Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2023-12-29Clinical Trial Update: Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A clinical trial evaluating CAR-T cells targeting CD19 and BCMA in relapsed or refractory multiple myeloma across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2023-12-19Clinical Trial Update: Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab [Phase 2]
This clinical trial update reports results from a Phase 2 study of retreatment with daratumumab in patients with multiple myeloma who had pr…
-
CLINICAL_TRIALS trial_result · 2023-12-19Clinical Trial Update: Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2) [Phase 1, Phase 2]
Clinical trial update for Zevor-cel (CT053) in relapsed/refractory multiple myeloma (LUMMICAR STUDY 2) spanning Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2023-12-18Clinical Trial Update: Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 [Phase 3]
A Phase 3 randomized trial in multiple myeloma compares lenalidomide, bortezomib, and dexamethasone (RVd) against high-dose chemotherapy wit…
-
EMA withdrawal · 2023-12-15EMA confirms recommendation for non-renewal of authorisation of multiple myeloma medicine Blenrep
EU CHMP confirmed recommendation not to renew the conditional marketing authorisation for Blenrep (belantamab mafodotin) due to lack of conf…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-12-15Clinical Trial Update: Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM) [Phase 2]
Phase 2 clinical trial update evaluating Uproleselan (GMI-1271) for prophylaxis of GI toxicity during melphalan-conditioned autologous stem …
-
CLINICAL_TRIALS trial_result · 2023-12-15Clinical Trial Update: Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma [Phase 2]
Phase 2 trial update of a second autologous stem cell transplant regimen using Elo-Pom-Dex for relapsed multiple myeloma; results were poste…
-
CLINICAL_TRIALS trial_result · 2023-12-13Clinical Trial Update: Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin [Phase 3]
Phase 3 trial update characterizing corneal epithelial changes in participants treated with belantamab mafodotin; study terminated with resu…
-
CLINICAL_TRIALS trial_result · 2023-12-13Clinical Trial Update: Maintenance Therapy With Subcutaneous Bortezomib [Phase 2]
Phase 2 trial evaluating maintenance therapy with subcutaneous bortezomib in multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2023-12-07Clinical Trial Update: NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"
A completed all-case surveillance trial evaluating NINLARO (ixazomib) capsules for relapsed/refractory multiple myeloma with posted results.
-
CLINICAL_TRIALS trial_result · 2023-12-06Clinical Trial Update: Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM [Phase 2]
Phase 2 study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma has completed and posted result…
-
CLINICAL_TRIALS trial_result · 2023-12-06Clinical Trial Update: ATG-010(Selinexor) in Combination With Chemotherapy in RRMM [Phase 2]
Phase 2 clinical trial update for ATG-010 (Selinexor) combined with chemotherapy in relapsed refractory multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2023-12-01Clinical Trial Update: Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma [Phase 1, Phase 2]
Clinical trial evaluating pomalidomide and dexamethasone with or without ixazomib for relapsed multiple myeloma across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2023-12-01Clinical Trial Update: A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating belantamab mafodotin in combination with daratumumab, lenalidomide, and dexamethasone for newly diagno…
-
CLINICAL_TRIALS trial_result · 2023-11-28Clinical Trial Update: Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older [Phase 2]
Phase 2 trial comparing autologous stem cell transplant with high-dose melphalan versus high-dose melphalan plus bortezomib in patients aged…
-
CLINICAL_TRIALS trial_result · 2023-11-24Clinical Trial Update: BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) [Phase 2]
Phase 2 trial update on BRAF/MEK inhibition for relapsed/refractory multiple myeloma with BRAFV600E/K mutations.
-
CLINICAL_TRIALS trial_result · 2023-11-22Clinical Trial Update: Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma [Phase 2]
Phase 2 clinical trial update on monoclonal antibody-based sequential therapy aiming for deep remission in multiple myeloma; results posted …
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies [Phase 2]
A Phase 2 clinical trial evaluating a COVID-19 vaccine booster dosing in patients with hematologic malignancies has completed enrollment and…
-
FDA approval · 2023-11-16FDA Approved: TECVAYLI — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for TECVAYLI (teclistamab-cqyv) to expand or modify its labeling for the treatment of multiple myelo…
-
FDA approval · 2023-11-16FDA Approved: TALVEY — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for TALVEY (talquetamab) from Janssen Biotech, Inc. The action updates the drug's labeling/indic…
-
CLINICAL_TRIALS trial_result · 2023-11-13Clinical Trial Update: A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A study update for CM313 in relapsed or refractory multiple myeloma spanning Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2023-11-09Clinical Trial Update: SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating SL-401 in combination with pomalidomide and dexamethasone in relapsed or relapsed/refractory multiple myeloma was…
-
CLINICAL_TRIALS trial_result · 2023-11-08Clinical Trial Update: Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet [Phase 2]
Phase 2 trial in early relapsed, lenalidomide-refractory multiple myeloma evaluated a carfilzomib-based triplet regimen; results have been p…
-
CLINICAL_TRIALS trial_result · 2023-11-08Clinical Trial Update: Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple Myeloma [Phase 2]
A Phase 2 clinical trial assessed whether hyperbaric oxygen improves blood count recovery after autologous stem cell transplantation in mult…
-
CLINICAL_TRIALS trial_result · 2023-11-07Clinical Trial Update: Short Course Daratumumab in Patients With Multiple Myeloma [Phase 2]
This report summarizes Phase 2 results for a short-course daratumumab regimen in patients with multiple myeloma, with the trial completed an…